A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 study whose purpose is see how useful investigational drug, avelumab, is in
patients with locally advanced or metastatic penile cancer who are unfit for or progressed on
platinum-based chemotherapy.
The usefulness of avelumab in this study population will be determined by anti-tumor activity
assessed by objective response rate.
Avelumab is a monoclonal antibody that binds to a protein called programmed death-ligand 1
(PD-L1) and blocks its communication with another protein called programmed death protein 1
(PD-1). The communication of these proteins are thought to be important in the growth of
tumors. Blocking these proteins from communicating may stop or shrink tumors.